Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

NCT05614115 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT05614115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2023
Completion date
June 30, 2025
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic, dialysis, end-stage kidney disease, hemodialysis, kidney disease, chronic, kidney dysfunction, kidney failure, non-diabetic